ReviewmAbs
Monoclonal antibodies and other biologic agents in the treatment of asthma.
Review in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.The Journal of allergy and clinical immunology · 2013Trial
- Immunotherapy for asthma.Cellular & molecular immunology · 2025Review
- Targeting IL-13 and IL-4 in Asthma: Therapeutic Implications on Airway Remodeling in Severe Asthma.Clinical reviews in allergy & immunology · 2025Review
- Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology.Journal of asthma and allergy · 2022Article
- Recent Advances in the Inhibition of the IL-4 Cytokine Pathway for the Treatment of Allergen-Induced Asthma.International journal of molecular sciences · 2021Review
- Interferon characterization associates with asthma and is a potential biomarker of predictive diagnosis.Bioscience reports · 2021Article
- The use of biologics in children with allergic rhinitis and chronic rhinosinusitis: Current updates.Pediatric investigation · 2019Review
- Review
- Critical review of bronchial thermoplasty: where should it fit into asthma therapy?Current allergy and asthma reports · 2014Review
- Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma.Biologics : targets & therapy · 2013Article
- Antagonism of cytokine-induced eosinophil accumulation in asthma.Frontiers in pharmacology · 2012Article
- The active contribution of Toll-like receptors to allergic airway inflammation.International immunopharmacology · 2011Review
- Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia.Acta pharmacologica Sinica · 2010Article
- Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma represents a syndrome of airway inflammatory diseases with complex pathology. The immunologic pathogenesis is being increasingly revealed and provides opportunity for targeted biological intervention. Current experience with immunomodulators as targeted therapy in asthma is described in this literature review. Targeted therapies have included strategies to activate dendritic cells through the TLR-9 receptors, to interrupt the action of T(H)2 cytokines with cytokine blockers and monoclonal antibodies, to promote development of T(H)1 responses, to block IgE mediated pathways and to block TNFalpha. Omalizumab is the only biological therapy that has an approved indication in asthma at this time. An improved understanding of the heterogeneity of asthma should allow for specific targeting of different disease phenotypes specific therapies including immunomodulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.